{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:00:39Z","timestamp":1793448039677,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s10585-022-10167-6","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T04:51:51Z","timestamp":1651726311000},"page":"581-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0731-8041","authenticated-orcid":false,"given":"Luca","family":"Nicosia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Figlia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ricottone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Mazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Giaj-Levra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ricchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Maria Magrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Girlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"issue":"2","key":"10167_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10549-017-4529-5","volume":"167","author":"JA Malmgren","year":"2018","unstructured":"Malmgren JA, Mayer M, Atwood MK, Kaplan HG (2018) Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990\u20132010. Breast Cancer Res Treat 167(2):579\u2013590","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10167_CR2","doi-asserted-by":"publisher","first-page":"pky062","DOI":"10.1093\/jncics\/pky062","volume":"2","author":"JL Caswell-Jin","year":"2018","unstructured":"Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW (2018) Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr. 2(4):pky062","journal-title":"JNCI Cancer Spectr."},{"issue":"20","key":"10167_CR3","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Andr\u00e9 F, Theall KP, Huang X, Giorgetti C, Bartlett CH, Cristofanilli M (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379(20):1926\u20131936","journal-title":"N Engl J Med"},{"issue":"20","key":"10167_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu Y-S, Inoue K, Takahashi M, P\u00e1pai Z, Longin A-S, Mills D, Wilke C, Hirawat S, Juric D, SOLAR-1 Study Group (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929\u20131940","journal-title":"N Engl J Med"},{"issue":"6","key":"10167_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM, Kim SB, Cort\u00e9s J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461\u2013471","journal-title":"Lancet Oncol"},{"issue":"7","key":"10167_CR6","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/annonc\/mdn057","volume":"19","author":"S Mahner","year":"2008","unstructured":"Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, Dose-Schwarz J (2008) Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-d-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19(7):1249\u20131254","journal-title":"Ann Oncol"},{"issue":"4","key":"10167_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000503847","volume":"15","author":"C Cha","year":"2020","unstructured":"Cha C, Ahn SG, Yoo TK, Kim KM, Bae SJ, Yoon C, Park S, Sohn J, Jeong J (2020) Local treatment in addition to endocrine therapy in hormone receptor-positive and HER2-negative oligometastatic breast cancer patients: a retrospective multicenter analysis. Breast Care (Basel) 15(4):408\u2013414","journal-title":"Breast Care (Basel)"},{"key":"10167_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8\u201310","journal-title":"J Clin Oncol"},{"key":"10167_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, M\u00e9ndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward WA (2020) Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol 148:157\u2013166","journal-title":"Radiother Oncol"},{"issue":"25","key":"10167_CR10","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830\u20132838. https:\/\/doi.org\/10.1200\/JCO.20.00818","journal-title":"J Clin Oncol"},{"key":"10167_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.breast.2018.09.006","volume":"42","author":"C Onal","year":"2018","unstructured":"Onal C, Guler OC, Yildirim BA (2018) Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. Breast 42:150\u2013156. https:\/\/doi.org\/10.1016\/j.breast.2018.09.006","journal-title":"Breast"},{"key":"10167_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3857\/roj.2015.33.4.301","volume":"33","author":"GS Yoo","year":"2015","unstructured":"Yoo GS, Yu JI, Park W, Huh SJ, Choi DH (2015) Prognostic factors in breast cancer with extracranial ligometastases and the appropriate role of radiation therapy. Radiat Oncol J 33:301\u2013309","journal-title":"Radiat Oncol J"},{"key":"10167_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.breast.2015.12.002","volume":"26","author":"M Scorsetti","year":"2016","unstructured":"Scorsetti M, Franceschini D, De Rose F, Comito T, Villa E, Iftode C, Navarria P, D\u2019Agostino GR, Masci G, Torrisi R, Testori A, Tinterri C, Santoro A (2016) Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer. Breast 26:11\u201317","journal-title":"Breast"},{"issue":"2","key":"10167_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.rpor.2016.07.008","volume":"22","author":"M Scorsetti","year":"2017","unstructured":"Scorsetti M, Franceschini D, De Rose F, Comito T, Franzese C, Masci G, Torrisi R, Vigan\u00f2 L, Torzilli G (2017) The role of SBRT in oligometastatic patients with liver metastases from breast cancer. Rep Pract Oncol Radiother Mar-Apr 22(2):163\u2013169","journal-title":"Rep Pract Oncol Radiother Mar-Apr"},{"issue":"1","key":"10167_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijrobp.2019.09.038","volume":"110","author":"A Sahgal","year":"2021","unstructured":"Sahgal A, Chang JH, Ma L, Marks LB, Milano MT, Medin P, Niemierko A, Soltys SG, Tom\u00e9 WA, Wong CS, Yorke E, Grimm J, Jackson A (2021) Spinal cord dose tolerance to stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 110(1):124\u2013136. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.09.038","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10167_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nec.2019.12.001","volume":"31","author":"FY Moraes","year":"2020","unstructured":"Moraes FY, Chen X, Yan M et al (2020) Evolving role of stereotactic body radiation therapy in the management of spine metastases: defining dose and dose constraints. Neurosurg Clin N Am 31(2):167\u2013189","journal-title":"Neurosurg Clin N Am"},{"issue":"1","key":"10167_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","volume":"30","author":"GG Hanna","year":"2018","unstructured":"Hanna GG, Murray L, Patel R, Jain S, Aitken KL, Franks KN, van As N, Tree A, Hatfield P, Harrow S, McDonald F, Ahmed M, Saran FH, Webster GJ, Khoo V, Landau D, Eaton DJ, Hawkins MA (2018) UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol 30(1):5\u201314","journal-title":"Clin Oncol"},{"issue":"3","key":"10167_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semradonc.2017.02.001","volume":"27","author":"EL Pollom","year":"2017","unstructured":"Pollom EL, Chin AL, Diehn M, Loo BW, Chang DT (2017) Normal tissue constraints for abdominal and thoracic stereotactic body radiotherapy. Semin Radiat Oncol 27(3):197\u2013208","journal-title":"Semin Radiat Oncol"},{"issue":"30","key":"10167_CR19","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","volume":"24","author":"R Timmerman","year":"2006","unstructured":"Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24(30):4833\u20134839","journal-title":"J Clin Oncol"},{"issue":"11","key":"10167_CR20","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jama.2010.261","volume":"303","author":"R Timmerman","year":"2010","unstructured":"Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11):1070\u20131076","journal-title":"JAMA"},{"issue":"3","key":"10167_CR21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","volume":"70","author":"C Park","year":"2008","unstructured":"Park C, Papiez L, Zhang S, Story M, Timmerman RD (2008) Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 70(3):847\u2013852","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"10167_CR22","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1002\/cam4.4068","volume":"10","author":"NA Wijetunga","year":"2021","unstructured":"Wijetunga NA, Dos Anjos CH, Zhi WI, Robson M, Tsai CJ, Yamada Y, Dover L, Gillespie EF, Xu AJ, Yang JT (2021) Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. Cancer Med 10(15):5163\u20135174","journal-title":"Cancer Med"},{"issue":"3","key":"10167_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00066-019-01523-9","volume":"196","author":"L Nicosia","year":"2020","unstructured":"Nicosia L, Franzese C, Mazzola R, Franceschini D, Rigo M, D\u2019agostino G, Corradini S, Alongi F, Scorsetti M (2020) Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. Strahlenther Onkol 196(3):213\u2013221","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"10167_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","volume":"83","author":"MT Milano","year":"2012","unstructured":"Milano MT, Katz AW, Zhang H, Okunieff P (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83(3):878\u2013886","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10167_CR25","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00432-020-03223-9","volume":"146","author":"L Nicosia","year":"2020","unstructured":"Nicosia L, Cuccia F, Mazzola R, Figlia V, Giaj-Levra N, Ricchetti F, Rigo M, Bon\u00f9 M, Corradini S, Tolia M, Alongi F (2020) Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. J Cancer Res Clin Oncol 146(9):2351\u20132358","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10167_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ijrobp.2019.02.033","volume":"104","author":"C Greco","year":"2019","unstructured":"Greco C, Pares O, Pimentel N, Louro V, Morales J, Nunes B, Castanheira J, Oliveira C, Silva A, Vaz S, Costa D, Zelefsky M, Kolesnick R, Fuks Z (2019) Phenotype-oriented ablation of oligometastatic cancer with single dose radiation therapy. Int J Radiat Oncol Biol Phys 104(3):593\u2013603","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10167_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12885-019-5362-5","volume":"19","author":"RJ Klement","year":"2019","unstructured":"Klement RJ, Abbasi-Senger N, Adebahr S, Alheid H, Allgaeuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Eble MJ, Ernst I, Gerum S, Habermehl D, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lewitzki V, Lohaus F, Ostheimer C, Papachristofilou A, Petersen C, Rieber J, Schneider T, Schrade E, Semrau R, Wachter S, Wittig A, Guckenberger M, Andratschke N (2019) The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer 19(1):173","journal-title":"BMC Cancer"},{"key":"10167_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2021.10.023","volume":"166","author":"L Nicosia","year":"2022","unstructured":"Nicosia L, Franceschini D, Perrone-Congedi F, Casamassima F, Gerardi MA, Rigo M, Mazzola R, Perna M, Scotti V, Fodor A, Iurato A, Pasqualetti F, Gadducci G, Chiesa S, Niespolo RM, Bruni A, Alicino G, Frassinelli L, Borghetti P, Di Marzo A, Ravasio A, De Bari B, Sepulcri M, Aiello D, Mortellaro G, Sangalli C, Franceschini M, Montesi G, Aquilanti FM, Lunardi G, Valdagni R, Fazio I, Scarzello G, Corti L, Vavassori V, Maranzano E, Magrini SM, Arcangeli S, Gambacorta MA, Valentini V, Paiar F, Ramella S, Di Muzio NG, Livi L, Jereczek-Fossa BA, Osti MF, Scorsetti M, Alongi F (2022) A multicenter large retrospectIve data base on the personalization of stereotactic ablative radiotherapy use in lung metastases from colon-rectal cancer: the LaIT-SABR study. Radiother Oncol 166:92\u201399. https:\/\/doi.org\/10.1016\/j.radonc.2021.10.023","journal-title":"Radiother Oncol"},{"issue":"5","key":"10167_CR29","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.ijrobp.2009.07.1751","volume":"81","author":"H Onishi","year":"2011","unstructured":"Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Karasawa K, Hayakawa K, Niibe Y, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Kozuka T, Arimoto T, Hara R, Itami J, Araki T (2011) Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 81(5):1352\u20131358","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10167_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","volume":"110","author":"N Ohri","year":"2021","unstructured":"Ohri N, Tom\u00e9 WA, M\u00e9ndez Romero A, Miften M, Ten Haken RK, Dawson LA, Grimm J, Yorke E, Jackson A (2021) Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys 110(1):188\u2013195. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.12.288","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7547","key":"10167_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem G, Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, H\u00f6gn\u00e4s G, Annala M, Kivinummi K, Goody V, Latimer C, Omeara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, Mcdermott U, Wedge DC, Bova GS (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353\u2013357","journal-title":"Nature"},{"key":"10167_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.radonc.2021.06.012","volume":"161","author":"H Tan","year":"2021","unstructured":"Tan H, Cheung P, Louie AV, Myrehaug S, Niglas M, Atenafu EG, Chu W, Chung HT, Poon I, Sahgal A, Soliman H (2021) Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: treatment indication matters. Radiother Oncol 161:159\u2013165","journal-title":"Radiother Oncol"},{"key":"10167_CR33","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3389\/fonc.2020.00987","volume":"10","author":"F Weykamp","year":"2020","unstructured":"Weykamp F, K\u00f6nig L, Seidensaal K, Forster T, Hoegen P, Akbaba S, Mende S, Welte SE, Deutsch TM, Schneeweiss A, Debus J, H\u00f6rner-Rieber J (2020) Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer. Front Oncol 10:987. https:\/\/doi.org\/10.3389\/fonc.2020.00987","journal-title":"Front Oncol"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-022-10167-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-022-10167-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-022-10167-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T11:06:00Z","timestamp":1659179160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-022-10167-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10167"],"URL":"https:\/\/doi.org\/10.1007\/s10585-022-10167-6","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"23 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}